RT Journal Article
SR Electronic
T1 Improvements in the incidence and survival of cancer and cardiovascular but not infectious disease have driven recent mortality improvements in Scotland: nationwide cohort study of linked hospital admission and death records 2001–2016
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19003012
DO 10.1101/19003012
A1 Paul RHJ Timmers
A1 Joannes J Kerssens
A1 Jon W Minton
A1 Ian Grant
A1 James F Wilson
A1 Harry Campbell
A1 Colin M Fischbacher
A1 Peter K Joshi
YR 2019
UL http://medrxiv.org/content/early/2019/08/05/19003012.abstract
AB Objectives To identify the causes and future trends underpinning improvements in life expectancy in Scotland and quantify the relative contributions of disease incidence and survival.Design Population-based study.Setting Linked secondary care and mortality records across Scotland.Participants 1,967,130 individuals born between 1905 and 1965, and resident in Scotland throughout 2001–2016.Main outcome measures Hospital admission rates and survival in the five years following admission for 28 diseases, stratified by sex and socioeconomic status.Results The five hospital admission diagnoses associated with the greatest burden of death subsequent to admission were “Influenza and pneumonia”, “Symptoms and signs involving the circulatory and respiratory systems”, “Malignant neoplasm of respiratory and intrathoracic organs”, “Symptoms and signs involving the digestive system and abdomen”, and “General symptoms and signs”. Using disease trends, we modelled a mean mortality hazard ratio of 0.737 (95% CI 0.730–0.745) across decades of birth, equivalent to a life extension of ∼3 years per decade. This improvement was 61% (30%–93%) accounted for by improvements in disease survival after hospitalisation (principally cancer) with the remainder accounted for by a fall in hospitalisation incidence (principally heart disease and cancer). In contrast, deteriorations in the incidence and survival of infectious diseases reduced mortality improvements by 9% (∼3.3 months per decade). Overall, health-driven mortality improvements were slightly greater for men than women (due to greater falls in disease incidence), and generally similar across socioeconomic deciles. We project mortality improvements will continue over the next decade but will slow down by 21% because much of the progress in disease survival has already been achieved.Conclusion Morbidity improvements broadly explain observed improvements in overall mortality, with progress on the prevention and treatment of heart disease and cancer making the most significant contributions. The gaps between men and women’s morbidity and mortality are closing, but the gap between socioeconomic groups is not. A slowing trend in improvements in morbidity may explain the stalling in improvements of period life expectancies observed in recent studies in the UK. However, our modelled slowing of improvements could be offset if we achieve even faster improvements in the major diseases contributing to the burden of death, or if we improve prevention and survival of diseases which have deteriorated recently, such as infectious disease, in the future.What is already known on this topicLong term improvements in Scottish mortality have slowed down recently, while life expectancy inequalities between socioeconomic classes are increasing.Deaths attributed to ischaemic heart disease and stroke in Scotland have declined in the last two decades.What this study addsGains in life expectancy can largely be attributed to improvements in cancer survival and falls in incidence of cancer and cardiovascular disease.The hospitalisation rate and survival of several infectious diseases have deteriorated, and for urinary infections, this decline has been more rapid in more socioeconomically deprived classes.Improvements in morbidity are projected to slow down, with much progress in survival of heart disease and cancer already achieved, and align with the recently observed slow-down in mortality improvements.Competing Interest StatementPKJ reports grants from Lloyds Banking Group, PLC, during the conduct of the study. This grant was in part used to pay for research costs of JJK and CMF. The remaining authors declare no competing interests.Funding StatementThe study was funded by the Lloyds Banking Group, for the creation, curation and dissemination of knowledge in the public interest, in particular to improve estimates of future population size and morbidity and mortality rates to facilitate healthcare and other government planning. All analyses stratified by socioeconomic deprivation (Table 2, Table 3, Supplementary Table 1, and Supplementary Data Files 1-5) were confidentially re-analysed using 10 socioeconomic groups specified by Lloyds, rather than the Scottish Index of Multiple Deprivation. No Lloyds employees were granted access to individual patient data. Data access was granted to University of Edinburgh researchers only and only through the national safe haven by the Public Benefit and Privacy Panel for Health and Social Care under application number 1617-0255/Joshi. The study and its design were conceived by the last author. The funder reviewed the design and said that adding stratification by socioeconomic status was a key requirement for meaningful analysis and their funding was conditional upon this, a request to which the authors readily agreed. The funder was kept informed of interim analyses and reviewed the draft manuscript, occasionally suggesting additional analyses or requesting clarifications. The funders were not permitted to and did not request the removal of any results. Authors affiliated with eDRIS and NHS Scotland were compensated by PKJ using the grant from Lloyds Banking Group, in line with normal pricing for the work undertaken. PRHJT was funded by the MRC Doctoral Training Programme (MR/N013166/1) and the University of Edinburgh College of Medicine and Veterinary Medicine. JFW was funded by the MRC QTL in health and disease. Apart from Lloyds Banking Group, the funders had no role in the study design, data collection, analysis, and interpretation, or the decision to submit the work for publication.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesIndividual de-identified participant data cannot be shared. Statistical code and technical details are available upon request from the corresponding author.